Lexis Nexis
Cook: Pharmaceuticals Biotechnology and the Law Fourth edition
One Year Subscription Only Terms
Subscribers receive the product(s) listed on the Order Form and any Updates made available during the annual subscription period. Shipping and handling fees are not included in the annual price.
Subscribers are advised of the number of Updates that were made to the particular publication the prior year. The number of Updates may vary due to developments in the law and other publishing issues, but subscribers may use this as a rough estimate of future shipments. Subscribers may call Customer Support at 800-833-9844 for additional information.
Subscribers may cancel this subscription by: calling Customer Support at 800-833-9844; emailing customer.support@lexisnexis.com; or returning the invoice marked 'CANCEL'.
If subscribers cancel within 30 days after the product is ordered or received and return the product at their expense, then they will receive a full credit of the price for the annual subscription.
If subscribers cancel between 31 and 60 days after the invoice date and return the product at their expense, then they will receive a 5/6th credit of the price for the annual subscription. No credit will be given for cancellations more than 60 days after the invoice date. To receive any credit, subscriber must return all product(s) shipped during the year at their expense within the applicable cancellation period listed above.
Product description
Why should you buy Cook: Pharmaceuticals Biotechnology and the Law Fourth edition
Written by a leading patent and regulatory lawyer, this text comprehensively covers the wide variety of legal and regulatory issues in the life sciences industry sector. This new edition has been fully revised, expanded and restructured to facilitate easy navigation, and has been updated to cover all the latest recent developments in legislation and case law, including preliminary material as to the likely effect of Brexit on the life sciences sector in both the UK and the EU27.
What's new
Regulatory- CJEU case law as to what constitutes genetic modification.
- Expanded and updated treatment of clinical trials, in particular the new clinical trials Regulation 536/2014/EC, the transparency of clinical trial data, and General Court and CJEU case law as to the latter.
- Expanded and updated treatment of medicinal products regulation, in particular advanced therapy medicinal products, pharmacovigilance, and the new veterinary medicinal products Regulation (EU) 2019/6 and recent CJEU case law on the medicinal products Directives.
- Expanded and updated treatment of medical devices regulation, in particular new Regulations 2017/745 on medical devices and 2017/746 on in vitro diagnostic medical devices and the current status of their implementation, and recent CJEU case law on issues under the Directives which these Regulations replace.
- Separate chapter on validity issues encountered with medical use patents including recent EPO national case law on plausibility as a threshold test after which sufficiency and inventive step analyses can be applied.
- Developments in the patenting of stem cells and of the products of essentially biological processes, and the ongoing controversy as to the latter involving the EU, the Administrative Council of the EPO, and the Boards of Appeal of the EPO.
- Separate chapter on infringement and enforcement issues other than in the context of generic entry, including the developing law on the effective scope of protection, proportionate injunctions and recent German case law on compulsory licences, and recent case law on 鈥渟kinny labelling鈥 and the protective scope of claims to medical uses when applied to products having such labels.
- Latest CJEU and National SPC case law and the new Regulation amending the medicinal products SPC Regulation to provide for a manufacturing waiver.
- Recent national and CJEU case law on data exclusivity, and the revision to the data exclusivity regime for veterinary effected by veterinary medicinal products Regulation (EU) 2019/6.
- Separate chapter on orphan medicinal products covering latest CJEU case law and the effect of amending Regulation (EU) 2018/781.
- Recent Commission, General Court and CJEU case law on competition law issues associated with generic entry.
- New treatment of post generic entry competition law issues that are not associated with IPRs and the approach to these adopted by the competition law authorities at a national level.
Related products
-
The Financing of Intangible Assets: TMT Finance and Emerging Technologies£268.00 -
Laddie, Prescott and Vitoria: The Modern Law of Copyright Fifth edition£833.00 -
Butterworths Company Law Handbook 33rd edition£189.99 -
The Modern Law of Patents Fourth edition£478.49 -
Butterworths Intellectual Property Law Handbook 14th edition£206.00